Pharma Focus Asia

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Collaboration

Friday, March 10, 2023

Alnylam Pharmaceuticals and Medison Pharma ("Medison”) announced an expansion of the existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.

This new agreement builds upon the successful long-term partnership between Alnylam and Medison in Israel and will allow Alnylam to utilise Medison's unique multi-regional platform to ensure that Alnylam's innovative RNA interference (RNAi) therapeutics, such as ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) are made available across additional countries in Europe. This expanded agreement is intended to ensure more efficient and effective commercialisation. GIVLAARI® and OXLUMO® have already been approved for reimbursement in Poland, and Alnylam and Medison will work together to obtain additional reimbursements in the territories.

The expansion of the existing relationship with Medison, will allow to strengthen the presence and bring the benefits of Alnylam's innovative RNAi therapies to patients in Central and Eastern Europe.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024